ClinicalTrials.gg
CompletedNCT00717093Updated Jul 23, 2015Results posted

Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

A Phase 4 interventional study of Varenicline Tartrate and Placebo in Tobacco Use Cessation, sponsored by Pfizer. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-23.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary goal of this study is to compare efficacy of varenicline to placebo for cessation of use of smokeless tobacco.

02

Conditions studied

  • Tobacco Use Cessation

Browse trials for

03

In context

Tobacco Use Cessation

276 studies on the registry are indexed under Tobacco Use Cessation; 45 are open to participants now.

This study's enrollment of 432 is above the median of 226 across 256 interventional studies indexed under Tobacco Use Cessation.

Browse Tobacco Use Cessation studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female daily smokeless tobacco users aged 18 years and older, who are motivated to stop use of all tobacco products.
  • Subjects must be daily users of nicotine containing smokeless tobacco and using smokeless tobacco on at least 8 occasions per day averaged over a week.
  • Have used smokeless tobacco for at least 1 year prior to screening with no period of abstinence >3 months in the past year.

Exclusion criteria

Exclusion Criteria:

  • Subjects using nicotine containing products (including smoking tobacco) other than smokeless tobacco for 3 months prior to screening.
  • Subjects with exhaled Carbon Monoxide (CO) >10 ppm at baseline.
  • Subjects who have used varenicline, bupropion, or NRT within 3 months of screening.
  • Subjects currently or within the past 12 months requiring treatment for depression or have a current or prior history of panic disorder, psychosis, bipolar disorder or any other serious mental illness.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    Active

    Drug: Varenicline Tartrate

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.

    Also known as: Champix, Chantix, CP-526,555

  • DrugPlacebo

    Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco

    Number of subjects who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) question: Has the subject used any nicotine-containing products in the last 7 days (Week 9) or since last study visit (Week 10 through 12) and confirmed salivary cotinine \<= 15 ng/mL.

    Time frame: Weeks 9 through 12

Secondary outcomes

  1. Number of Subjects With Continuous Abstinence (CA) of Smokeless Tobacco Use

    Number of subjects who remainded abstinent from the period defined as start of the primary endpoint (Week 9) through the end of follow up (Week 26) by reporting no use of nicotine-containing products and confirmed salivary cotinine \<= 15 ng/mL.

    Time frame: Week 9 through 12, Week 26

  2. Number of Subjects With Long Term Quit Rate (LTQR) of Smokeless Tobacco

    Number of subjects who were responders for the primary endpoint (4-week CQR for Weeks 9 through 12) and who had no more than 6 cumulative days of using nicotine containing products from Week 12 through Week 26.

    Time frame: Week 26

  3. Number of Subjects With 7-day Point Prevalence (PP) of Abstinence at the End of Treatment (Week 12) and at the End of Study (Week 26)

    Number of subjects at Week 12 and Week 26 reporting no use of nicotine-containing products in the last 7 days and confirmed salivary cotinine \<= 15 ng/mL.

    Time frame: Week 12, Week 26

07

Results

Posted May 18, 2010

Participant flow

Participant flow — Overall Study
MilestoneVarenicline TartratePlacebo
Started214218
Received treatment213218
Completed170170
Not completed4448
Withdrew: Adverse event199
Withdrew: Lack of efficacy313
Withdrew: Lost to follow-up96
Withdrew: Withdrawal by subject1219
Withdrew: Other01
Withdrew: Randomized but not treated10

Outcome measures

PrimaryNumber of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco

Number of subjects who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) question: Has the subject used any nicotine-containing products in the last 7 days (Week 9) or since last study visit (Week 10 through 12) and confirmed salivary cotinine \<= 15 ng/mL.

Time frame:
Weeks 9 through 12
Reported as:
Number · participants
Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco
participantsVarenicline TartratePlacebo
Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco12585
Statistical analysis
  • Varenicline Tartrate vs Placebo · Regression, Logistic · p = <0.0001 (p-values obtained from logistic regression model including main effects of treatment and center) · Odds ratio (or): 2.39 · 95% CI 1.59 to 3.58Odds ratio obtained from logistic regression model including main effects of treatment and center
SecondaryNumber of Subjects With Continuous Abstinence (CA) of Smokeless Tobacco Use

Number of subjects who remainded abstinent from the period defined as start of the primary endpoint (Week 9) through the end of follow up (Week 26) by reporting no use of nicotine-containing products and confirmed salivary cotinine \<= 15 ng/mL.

Time frame:
Week 9 through 12, Week 26
Reported as:
Number · participants
Number of Subjects With Continuous Abstinence (CA) of Smokeless Tobacco Use
participantsVarenicline TartratePlacebo
Week 9140101
Week 1013596
Week 1113293
Week 1212585
Week 269573
Statistical analysis
  • Varenicline Tartrate vs Placebo · Regression, Logistic · p = 0.0118 (p-value obtained from a logistic regression model including the main effects of treatment and center) · Odds ratio (or): 1.70 · 95% CI 1.12 to 2.58Odds Ratio obtained from a logistic regression model including the main effects of treatment and center
SecondaryNumber of Subjects With Long Term Quit Rate (LTQR) of Smokeless Tobacco

Number of subjects who were responders for the primary endpoint (4-week CQR for Weeks 9 through 12) and who had no more than 6 cumulative days of using nicotine containing products from Week 12 through Week 26.

Time frame:
Week 26
Reported as:
Number · participants
Number of Subjects With Long Term Quit Rate (LTQR) of Smokeless Tobacco
participantsVarenicline TartratePlacebo
Number of Subjects With Long Term Quit Rate (LTQR) of Smokeless Tobacco10278
Statistical analysis
  • Varenicline Tartrate vs Placebo · Regression, Logistic · p = 0.0063 · Odds ratio (or): 1.77 · 95% CI 1.17 to 2.67Missing salivary cotinine values were imputed as negative.
SecondaryNumber of Subjects With 7-day Point Prevalence (PP) of Abstinence at the End of Treatment (Week 12) and at the End of Study (Week 26)

Number of subjects at Week 12 and Week 26 reporting no use of nicotine-containing products in the last 7 days and confirmed salivary cotinine \<= 15 ng/mL.

Time frame:
Week 12, Week 26
Reported as:
Number · participants
Number of Subjects With 7-day Point Prevalence (PP) of Abstinence at the End of Treatment (Week 12) and at the End of Study (Week 26)
participantsVarenicline TartratePlacebo
Week 1212385
Week 2610288
Statistical analysis
  • Varenicline Tartrate vs Placebo · Regression, Logistic · p = <0.0001 (p-value obtained from a logistic regression model including the main effects of treatment and center) · Odds ratio (or): 2.28 · 95% CI 1.52 to 3.41Odds ratio obtained from a logistic regression model including the main effects of treatment and center
  • Varenicline Tartrate vs Placebo · Regression, Logistic · p = 0.0919 (p-value obtained from a logistic regression model including the main effects of treatment and center) · Odds ratio (or): 1.42 · 95% CI 0.94 to 2.13Odds ratio obtained from a logistic regression model including the main effects of treatment and center

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline Tartrate—2/213 (0.9%)151/213 (70.9%)
Placebo—3/218 (1.4%)107/218 (49.1%)
Most frequent serious events
Most frequent serious events
EventVarenicline TartratePlacebo
Post procedural haemorrhageInjury, poisoning and procedural complications1/2130/218
Road traffic accidentInjury, poisoning and procedural complications1/2130/218
Loss of consciousnessNervous system disorders1/2130/218
Cardiac failureCardiac disorders0/2131/218
Tendon ruptureInjury, poisoning and procedural complications0/2131/218
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2131/218
Most frequent other events
Showing 10 of 33
Most frequent other events
EventVarenicline TartratePlacebo
NauseaGastrointestinal disorders74/21314/218
FatigueGeneral disorders22/21315/218
HeadacheNervous system disorders22/21320/218
Sleep disorderPsychiatric disorders22/21315/218
FlatulenceGastrointestinal disorders18/2137/218
Abnormal dreamsPsychiatric disorders17/2133/218
InsomniaPsychiatric disorders13/2136/218
NasopharyngitisInfections and infestations12/2138/218
Abdominal pain upperGastrointestinal disorders11/2135/218
IrritabilityGeneral disorders11/2139/218

Baseline characteristics

Age, Customized
Age, Customized(participants)Varenicline TartratePlaceboTotal
18 - 44 years117115232
45 - 64 years8893181
>= 65 years81018
Sex: Female, Male
Sex: Female, Male(Participants)Varenicline TartratePlaceboTotal
Female242246
Male189196385
08

Study locations

16 sites
  • Pfizer Investigational Site
    Floro, 6900, Norway
  • Pfizer Investigational Site
    Hafrsfjord, 4042, Norway
  • Pfizer Investigational Site
    Hamar, 2317, Norway
  • Pfizer Investigational Site
    Hønefoss, 3515, Norway
  • Pfizer Investigational Site
    Oslo, 0407, Norway
  • Pfizer Investigational Site
    Radal, 5235, Norway
  • Pfizer Investigational Site
    Trondheim, 7034, Norway
  • Pfizer Investigational Site
    Göteborg, 413 45, Sweden
  • Pfizer Investigational Site
    Helsingborg, 254 52, Sweden
  • Pfizer Investigational Site
    Jarfalla, 177 31, Sweden
  • Pfizer Investigational Site
    Karlstad, 652 24,, Sweden
  • Pfizer Investigational Site
    Orebro, 701 85, Sweden
  • Pfizer Investigational Site
    Sodertalje, 151 87, Sweden
  • Pfizer Investigational Site
    Stockholm, 118 91, Sweden
  • Pfizer Investigational Site
    Sundsvall, 852 31, Sweden
  • Pfizer Investigational Site
    Umea, 901 85, Sweden
09

References and documents

Publications

  • Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010 Dec 6;341:c6549. doi: 10.1136/bmj.c6549. PubMed 21134997 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Apr 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2008
First posted
Jul 16, 2008
Start
Aug 2008
Primary completionActual
Apr 2009
CompletionActual
Jul 2009
Results first posted
May 18, 2010
Last update
Jul 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00717093
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 16, 2008
Start date
Aug 2008
Primary completion
Apr 2009
Completion
Jul 2009
Results posted
May 18, 2010
Last update
Jul 23, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion